Description

DOTA-JR11 (also known as Satoreotide Tetraxetan) is a synthetic peptide that functions as a somatostatin receptor 2 (SSTR2) antagonist. It has been investigated for its potential in imaging and treating neuroendocrine tumors (NETs) by facilitating peptide receptor radionuclide therapy (PRRT). DOTA-JR11 can be labeled with isotopes like Gallium-68 (68Ga) for positron emission tomography (PET) imaging, aiding in the diagnosis and treatment planning for NETs. Manufactured under GMP conditions with ?98.81% purity, it is suitable for laboratory research applications. Strictly for laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

DOTA-JR11 acts as an antagonist of the somatostatin receptor 2 (SSTR2), which is overexpressed in many neuroendocrine tumors. By binding to SSTR2, DOTA-JR11 can be radiolabeled with isotopes such as Gallium-68 (68Ga) for PET imaging, aiding in the diagnosis and treatment planning for NETs. It is utilized in laboratory research to study its effects on tumor imaging and therapy. Strictly for laboratory research use only.

Side Effects (For Reference Only in Models)

Known side effects from clinical use of SSTR2 antagonists include nausea, vomiting, and potential risk of pancreatitis. These effects are valuable for interpreting experimental results and ensuring safety in laboratory environments. Strictly for laboratory research use only.

Disclaimer

This product is intended strictly for laboratory research use only. It is not approved for human or veterinary use. Handle according to institutional safety protocols.